Sumant Kulkarni
Stock Analyst at Canaccord Genuity
(2.29)
# 2,850
Out of 5,099 analysts
119
Total ratings
41.12%
Success rate
-0.57%
Average return
Main Sectors:
Stocks Rated by Sumant Kulkarni
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CYBN Cybin | Maintains: Buy | $70 → $45 | $5.97 | +653.77% | 9 | Nov 20, 2025 | |
| MNMD Mind Medicine (MindMed) | Maintains: Buy | $16 → $25 | $12.38 | +101.94% | 2 | Nov 7, 2025 | |
| ZVRA Zevra Therapeutics | Maintains: Buy | $25 → $24 | $8.45 | +184.02% | 7 | Nov 6, 2025 | |
| STOK Stoke Therapeutics | Maintains: Buy | $24 → $28 | $34.15 | -18.01% | 4 | Nov 5, 2025 | |
| NBIX Neurocrine Biosciences | Maintains: Buy | $160 → $164 | $155.63 | +5.38% | 17 | Oct 29, 2025 | |
| ATAI Atai Beckley | Maintains: Buy | $11 → $14 | $4.33 | +223.33% | 4 | Oct 22, 2025 | |
| ANVS Annovis Bio | Maintains: Buy | $17 | $4.20 | +304.76% | 4 | Sep 30, 2025 | |
| CLNN Clene | Maintains: Buy | $83 → $48 | $6.68 | +618.56% | 6 | Aug 18, 2025 | |
| CMPS COMPASS Pathways | Maintains: Buy | $15 | $6.69 | +124.22% | 4 | Aug 1, 2025 | |
| CRVO CervoMed | Maintains: Buy | $21 → $27 | $8.67 | +211.42% | 6 | Jul 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $265 → $220 | $177.55 | +23.91% | 21 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $14 → $12 | $4.42 | +171.49% | 5 | Mar 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $112 → $80 | $2.19 | +3,552.97% | 7 | Jan 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $31 → $28 | $14.22 | +96.91% | 4 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $33 | $26.81 | +23.09% | 13 | Mar 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $101 → $150 | $10.60 | +1,315.09% | 4 | Aug 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $29.80 | - | 2 | Jan 31, 2017 |
Cybin
Nov 20, 2025
Maintains: Buy
Price Target: $70 → $45
Current: $5.97
Upside: +653.77%
Mind Medicine (MindMed)
Nov 7, 2025
Maintains: Buy
Price Target: $16 → $25
Current: $12.38
Upside: +101.94%
Zevra Therapeutics
Nov 6, 2025
Maintains: Buy
Price Target: $25 → $24
Current: $8.45
Upside: +184.02%
Stoke Therapeutics
Nov 5, 2025
Maintains: Buy
Price Target: $24 → $28
Current: $34.15
Upside: -18.01%
Neurocrine Biosciences
Oct 29, 2025
Maintains: Buy
Price Target: $160 → $164
Current: $155.63
Upside: +5.38%
Atai Beckley
Oct 22, 2025
Maintains: Buy
Price Target: $11 → $14
Current: $4.33
Upside: +223.33%
Annovis Bio
Sep 30, 2025
Maintains: Buy
Price Target: $17
Current: $4.20
Upside: +304.76%
Clene
Aug 18, 2025
Maintains: Buy
Price Target: $83 → $48
Current: $6.68
Upside: +618.56%
COMPASS Pathways
Aug 1, 2025
Maintains: Buy
Price Target: $15
Current: $6.69
Upside: +124.22%
CervoMed
Jul 29, 2025
Maintains: Buy
Price Target: $21 → $27
Current: $8.67
Upside: +211.42%
May 2, 2025
Maintains: Buy
Price Target: $265 → $220
Current: $177.55
Upside: +23.91%
Mar 13, 2025
Maintains: Buy
Price Target: $14 → $12
Current: $4.42
Upside: +171.49%
Jan 6, 2025
Maintains: Buy
Price Target: $112 → $80
Current: $2.19
Upside: +3,552.97%
Nov 18, 2024
Maintains: Buy
Price Target: $31 → $28
Current: $14.22
Upside: +96.91%
Mar 12, 2024
Maintains: Buy
Price Target: $40 → $33
Current: $26.81
Upside: +23.09%
Aug 3, 2021
Maintains: Buy
Price Target: $101 → $150
Current: $10.60
Upside: +1,315.09%
Jan 31, 2017
Upgrades: Buy
Price Target: n/a
Current: $29.80
Upside: -